An observational study in Conversion Disorder, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-29.
Sponsored by Massachusetts General Hospital · Observational
Functional Neurological Disorder (FND/ Conversion Disorder) is a highly prevalent and disabling neuropsychiatric condition. Motor FND symptoms include Nonepileptic Seizures, Functional Movement Disorders and Functional Weakness. Clinical research across these motor FND subtypes, including research studies from the candidate's laboratory, suggest that these populations share many clinical and phenotypic similarities that warrant increased research integration. Furthermore, despite the prevalence of motor FND, little is known about the underlying pathophysiology of this condition, which is a prerequisite for the development of biologically informed prognostic and treatment response biomarkers. Across 3 published neurobiologically focused articles, the candidate proposed a framework through which to conceptualize motor FND. It is suggested that motor FND develops in the context of structural and functional alterations in neurocircuits mediating emotion awareness/expression, bodily awareness, viscerosomatic processing and behavioral regulation. The overall goal of this project is to comprehensively investigate structural and functional magnetic resonance imaging (MRI) biomarkers of prognosis across motor FND. Multimodal structural and functional MRI techniques (including voxel-based morphometry, cortical thickness, resting-state functional connectivity and diffusion tensor imaging tractography) will be used to systemically probe brain-prognosis relationships. Novel aspects of this proposal include the study of the full spectrum of motor FND, consistent with a trans-diagnostic approach.
Functional Neurological Disorder (FND) (Conversion Disorder) is a poorly understood and prevalent somatoform disorder, making up 16% of outpatient neurology referrals. Patients with motor FND (mFND) are difficult to treat, result in major morbidity, and are costly to the US. An estimated $256 billion is spent annually treating this population. mFND includes Nonepileptic Seizures (NES), Functional Movement Disorders (FMD) and Functional Weakness (FW). An impediment to managing mFND is the lack of a neurobiological understanding for this disorder. The diagnosis of mFND is currently based on qualitative aspects of behaviors, which may be difficult to interpret, and the absence of findings characteristic of other neuropsychiatric disorders on laboratory studies such as electroencephalography (EEG) and magnetic resonance imaging (MRI).
A major step forward would be the identification of neuroimaging biomarkers for mFND. mFND is understudied compared to other disorders, but recent studies point to distributed neurocircuit alterations associated with mFND. This project aims to advance our biological understanding of mFND by investigating neuroimaging biomarkers linked to prognosis. An improved understanding of the pathophysiology of mFND will provide a critical step in elucidating diagnostic, prognostic and treatment response biomarkers.
Aim:
Identify structural and functional biomarkers of prognosis at 6-months in patients with motor functional neurological disorders receiving an updated standard of care.
H1: Favorable mFND prognosis at 6 months post initial evaluation will be predicted by the degree of preserved baseline gray matter in limbic-paralimbic regions, particularly those part of the salience network.
H2: Favorable mFND prognosis at 6 months post initial evaluation will be predicted by the degree of preserved baseline resting-state functional connectivity in limbic/paralimbic areas, particularly those part of the salience network.
H3: Favorable mFND prognosis at 6 months will correlate with the degree of preserved baseline cingulum bundle and cingulum-insular tract integrity.
102 studies on the registry are indexed under Conversion Disorder; 36 are open to participants now.
This study's enrollment of 30 is below the median of 60 across 42 observational studies indexed under Conversion Disorder.
Browse Conversion Disorder studies →Massachusetts General Hospital is the lead sponsor of 2,582 studies on the registry; 451 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Recruitment will occur from patients receiving care in the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness. Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic. The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following: 1. Delivery of a positive "rule-in" diagnosis of functional neurological disorder 2. Individuals are provided with educational materials on functional neurological disorders 3. Referred to physical therapy and/or occupational therapy as clinically indicated 4. FND related cognitive behavioral therapy (CBT) referral when appropriate 5. Psychotropic medication management based on standard psychiatric care
Other: Standard of Care
The standard of care interventions for Functional Neurological Disorders (FND) include: 1. delivery of a rule-in diagnosis 2. providing educational materials 3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated 4. referring to FND-related cognitive behavioral therapy (CBT) 5. psychotropic medication management based on standard psychiatric care
Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison
Correcting for multiple comparisons in structural analyses, baseline structural grey matter volumes in limbic/paralimbic regions (particularly those affiliated with the salience network), would relate to clinical outcome in individuals receiving the standard of care at 6 months. Analyses reported refer to change in either mental health or physical health scores and baseline gray matter volume. The number presented is the peak voxel z-score as also reported in Supplementary Table 4 of the published manuscript. Z-scores are presented in absolute values (with the lowest value being 0). A higher z-score represents a stronger correlation between a given gray matter volume value (at the peak voxel) and the measure of interest (in case mental health or physical health scores). The entry under "row title" specifies if the association is a "positive" vs a "negative" association.
Time frame: baseline and 6 months
Resting State Functional Connectivity Strength Biomarkers of 6 Month Prognosis - Within Group Comparison
Correcting for multiple comparisons in resting state connectivity analyses, baseline functional connectivity strength (t-statistic scores) across limbic/paralimbic regions (particularly those affiliated with the salience network), would relate to clinical outcome in individuals receiving the standard of care at 6 months. Here, we tested if link-step connectivity from primary motor areas or amygdala nuclei related to change in clinical outcome. Specifically, we are providing the t-statistic for the connectivity strength between left centromedial amygdala to right anterior insula. Functional connectivity strength is based on the correlation of low frequency brain oscillations measured at rest. A large t-statistic value reflects greater connectivity between brain voxels.
Time frame: baseline and 6 months
The Integrity of Specific White Matter Tracts (Fractional Anisotropy) as Measured by Diffusion Tensor Imaging (DTI) Tractography Will Relate to 6-month Prognosis
Baseline integrity of the cingulum bundle and cingulate-insular tracts, as measured by fractional anisotropy, would relate to 6 month prognosis in patients with Functional Neurological Disorders (FND) receiving the standard of care. Outcome was not assessed - no time to analyze data given prior challenges with the pandemic. Unable to report data in any table as the white matter images have not been analyzed.
Time frame: baseline and 6 months
| Milestone | Motor Functional Neurological Disorder. |
|---|---|
| Started | 30 |
| Completed | 22 |
| Not completed | 8 |
Correcting for multiple comparisons in structural analyses, baseline structural grey matter volumes in limbic/paralimbic regions (particularly those affiliated with the salience network), would relate to clinical outcome in individuals receiving the standard of care at 6 months. Analyses reported refer to change in either mental health or physical health scores and baseline gray matter volume. The number presented is the peak voxel z-score as also reported in Supplementary Table 4 of the published manuscript. Z-scores are presented in absolute values (with the lowest value being 0). A higher z-score represents a stronger correlation between a given gray matter volume value (at the peak voxel) and the measure of interest (in case mental health or physical health scores). The entry under "row title" specifies if the association is a "positive" vs a "negative" association.
| peak voxel z-score | Motor Functional Neurological Disorder. |
|---|---|
| ∆SF-36 Mental Health Positive Associations: R supplementary motor area (6): 10mm, -16mm, 75mm | 4.18 |
| ∆SF-36 Mental Health Positive Associations: R superior frontal gyrus (6): 18mm, -7mm, 72mm | 3.27 |
| ∆SF-36 Mental Health Positive Associations: R middle cingulate gyrus (24): 3mm, 12mm, 43mm | 3.85 |
| ∆SF-36 Mental Health Positive Associations: L anterior hippocampus: -34mm, -16mm, -15mm | 3.76 |
| ∆SF-36 Mental Health Positive Associations: L middle frontal gyrus (46): -33mm, 26mm, 40mm | 3.61 |
| ∆SF-36 Physical Health Positive Associations: R frontopolar cortex (10): 10mm, 62mm, 4mm | 3.90 |
| ∆SF-36 Physical Health Negative Associations: R superior/middle frontal gyrus (9): 22mm, 24mm, 37mm | 4.40 |
| ∆SF-36 Physical Health Negative Associations: L superior occipital gyrus (19): -10mm, -82mm, 45mm | 3.80 |
| ∆SF-36 Physical Health Negative Associations: L superior occipital gyrus (19): -18mm, -78mm, 42mm | 3.70 |
Correcting for multiple comparisons in resting state connectivity analyses, baseline functional connectivity strength (t-statistic scores) across limbic/paralimbic regions (particularly those affiliated with the salience network), would relate to clinical outcome in individuals receiving the standard of care at 6 months. Here, we tested if link-step connectivity from primary motor areas or amygdala nuclei related to change in clinical outcome. Specifically, we are providing the t-statistic for the connectivity strength between left centromedial amygdala to right anterior insula. Functional connectivity strength is based on the correlation of low frequency brain oscillations measured at rest. A large t-statistic value reflects greater connectivity between brain voxels.
| t-statistic | Motor Functional Neurological Disorder. |
|---|---|
| Resting State Functional Connectivity Strength Biomarkers of 6 Month Prognosis - Within Group Comparison | 4.58 |
Baseline integrity of the cingulum bundle and cingulate-insular tracts, as measured by fractional anisotropy, would relate to 6 month prognosis in patients with Functional Neurological Disorders (FND) receiving the standard of care. Outcome was not assessed - no time to analyze data given prior challenges with the pandemic. Unable to report data in any table as the white matter images have not been analyzed.
No measurements were reported for this outcome.
Collected over 5 years of research funding. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Motor Functional Neurological Disorder. | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Age, Continuous(years) | Motor Functional Neurological Disorder. |
|---|---|
| Mean | 41.7 ± 11.0 |
| Sex: Female, Male(Participants) | Motor Functional Neurological Disorder. |
|---|---|
| Female | 19 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Motor Functional Neurological Disorder. |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 22 |
| Region of Enrollment(Participants) | Motor Functional Neurological Disorder. |
|---|---|
| United States | 22 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
Ran from Sep 2017 to primary completion in Jan 2023, 64 months.
Results were first posted in Aug 2023, 7 months after primary completion.
Of 19 observational studies under Conversion Disorder, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 55. This study's 64 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →